Top-News
Bio-Techne Announces New Customer Experience Centre in Düsseldorf, Germany
MINNEAPOLIS, March 26, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will open a new Customer Experience Centre in Düsseldorf, Germany to serve customers across the Europe, Middle East and Africa (EMEA) region and support the company's long-term regional growth strategy.
The new Customer Experience Centre is scheduled to open in summer 2026 and will feature a state-of-the-art Demonstration Laboratory hosting Bio-Techne's full instrument portfolio, including:
- The recently launched Leo™ System, powered by Simple Western™ Technology, which offers the throughput and precision of standard ELISAs in a fully automated western blot assay, expanding applications in bioanalytical workflows from discovery through commercialization.
- The best-in-class spatial biology platform, COMET™, which is the only fully-automated, high-throughput, hyperplex platform with superior tissue profiling capabilities.
"Our new Customer Experience Centre will complement our existing Demonstration Laboratory in the UK, enabling us to provide more customers with hands-on experience of our unique instrument portfolio, and demonstrate how our solutions can accelerate their cutting-edge science and bring next generation therapies to market faster," said Dr. Peter Schuessler, Vice President, EMEA, Bio-Techne.
The facility's capacity will enable Bio-Techne to grow its customer-facing team in EMEA and support long-term regional growth, including in the large German market.
Düsseldorf was carefully chosen as the site for this new centre due to its thriving life sciences sector and strategic proximity to the Benelux region, providing seamless access to customers from multiple European markets.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit http://www.bio-techne.com or follow the Company on social media at Facebook, LinkedIn, Twitter or YouTube.
About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-announces-new-customer-experience-centre-in-dusseldorf-germany-302409810.html
SOURCE Bio-Techne Corporation
Für dich aus unserer Redaktion zusammengestellt
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.